Skip to main content
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest Content
Archive
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest Content
Archive
Authors
About
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
Archive
Volume 10, Issue 1
Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13)
Email alerts
Article metrics
Article menu
Article
Text
Article
info
Citation
Tools
Share
Rapid Responses
Article
metrics
Alerts
PDF
Inflammatory bowel disease
Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13)
Online download statistics by month:
Online download statistics by month: February 2023 to March 2024
Abstract
Full
Pdf
Feb 2023
510
518
98
Mar 2023
342
345
85
Apr 2023
157
157
50
May 2023
133
134
37
Jun 2023
66
67
24
Jul 2023
53
48
14
Aug 2023
41
40
10
Sep 2023
64
66
15
Oct 2023
78
78
22
Nov 2023
83
84
19
Dec 2023
73
73
15
Jan 2024
61
61
21
Feb 2024
43
42
18
Mar 2024
58
61
46
Total
1762
1774
474
Read the full text or download the PDF:
Subscribe
Log in
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
PDF